Immune Hydrops

Slide 1 · Immune hydrops

Maternal–fetal blood group incompatibility, hemolysis, and fetal consequences

Etiology • Alloimmunity • Fetal pathology • Clinical consequences

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

1

Trace maternal sensitization to fetal red-cell destruction.

2

Explain the contrasting clinical patterns of RhD and ABO incompatibility.

3

Connect anemia and bilirubin excess to hydrops and kernicterus.

4

Identify source-described preventive and therapeutic approaches.

Slide 3 · Immune hydrops begins with red-cell alloimmunization

Fetal red-cell antigen

Maternal alloantibody

Placental transfer of IgG

Fetal red-cell destruction

Severe fetal hemolysis can culminate in generalized fluid accumulation.

Slide 4 · Hemolytic disease and hydrops are not synonyms

Hemolytic disease

Maternal antibody destroys fetal or neonatal erythrocytes.

Mild cases may be compensated without generalized edema.

Hydrops fetalis

Severe fluid accumulation is a downstream manifestation.

Requires sufficiently severe physiological derangement.

Slide 5 · Fetal hydrops is pathologic fluid accumulation

Core process

Edema fluid accumulates during intrauterine development.

Most severe phenotype

Generalized fetal edema and anasarca.

Lesser fluid collections

Pleural, peritoneal, or postnuchal collections can occur.

Slide 6 · Fluid distribution reflects disease severity

Fetal fluid accumulation

Localized

Pleural or peritoneal effusion

Postnuchal

Cystic hygroma; Often a nonimmune clue

Generalized

Hydrops fetalis / anasarca

Slide 7 · Modern hydrops is more often nonimmune

Historically

Rh-associated hemolytic anemia was a dominant cause.

Maternal alloimmunization commonly affected later pregnancies.

With Rh prophylaxis

Immune hydrops has become less frequent.

Nonimmune causes now predominate overall.

Slide 8 · The lecture focuses on the immune pathway

Cause of hydrops

Primary mechanism

Lecture emphasis

Immune

Maternal antibodies against fetal red cells

RhD and ABO-associated hemolysis

Nonimmune

Cardiac, genetic, infectious, or other anemia mechanisms

Short differential comparison only

Cause of hydrops

Primary mechanism

Lecture emphasis

Slide 9 · Antigen inheritance creates maternal–fetal mismatch

RhD-negative

Mother

RhD-positive

Fetus

A fetus can inherit a red-cell antigen from the father that the mother lacks.

Slide 10 · RhD is the principal Rh antigen discussed

The Rh blood group system comprises multiple antigens.

The D antigen as the major cause of clinically significant Rh incompatibility.

The relevant exposure is fetal RhD-positive erythrocytes entering a RhD-negative mother.

RhD mismatch is a prerequisite for RhD alloimmunization—not proof that disease will occur.

Slide 11 · Sensitization requires fetal cells to reach the mother

RhD-positive fetal erythrocytes

Fetomaternal passage

Maternal antigen recognition

Primary immune response

Exposure can occur before birth or during childbirth.

Slide 12 · Maternal exposure may occur late in pregnancy

Antepartum route

Fetal red cells can enter the maternal circulation during late pregnancy.

The placental barrier changes with advancing gestation.

Delivery route

Childbirth can mix fetal red cells into maternal blood.

Exposure may sensitize the mother after the first pregnancy.

Slide 13 · The first response is predominantly IgM

First antigen exposure

Maternal immune system encounters RhD.

Primary response

Initial antibody production includes IgM.

Limited fetal transfer

IgM does not efficiently cross the placenta.

Slide 14 · Placental transfer differs for IgM and IgG

Maternal blood

Fetal blood

P

L

A

C

E

N

T

A

IgG

Reaches fetus

IgM

Does not cross

Maternal IgG can enter fetal circulation; IgM is largely excluded.

Slide 15 · Immune memory changes a later exposure

Initial RhD exposure

Maternal immunologic memory

Renewed fetal RhD exposure

Accelerated IgG response

This is the classic explanation for greater RhD risk in later pregnancies.

Slide 16 · A subsequent pregnancy can trigger brisk IgG

Sensitized mother

Immunologic memory to RhD exists.

RhD-positive fetus

Antigen exposure is renewed.

IgG alloantibody

Placenta transfers antibody to fetal blood.

Slide 17 · Transferred IgG binds fetal erythrocytes

Anti-D IgG

Maternal circulation

RhD-positive RBCs

Fetal circulation

IgG antibody

The fetal red cell is recognized because it expresses the target antigen.

Slide 18 · Antibody-coated red cells are cleared

Fetal RhD-positive RBC

Maternal IgG attaches

Red-cell–antibody complex

Phagocytic removal

Destruction by phagocytes following antibody attachment.

Slide 19 · Rh hemolytic disease is a multistage process

Maternal stage

Exposure, sensitization, and IgG generation.

Placental stage

Movement of maternal IgG into fetal circulation.

Fetal stage

Red-cell clearance, anemia, and systemic consequences.

Slide 20 · First pregnancies are relatively spared—not immune

Why risk is usually lower

Primary RhD exposure often generates IgM first.

Sensitization commonly occurs at delivery.

Why risk is not zero

Antigen exposure can precede delivery.

A mother may already have been sensitized by a previous transfusion or fetal exposure.

Slide 21 · Antigen dose modifies immunization

Fetomaternal hemorrhage

Dose of fetal RhD antigen

Magnitude of maternal response

Risk of sensitization

The Robbins excerpt links risk to immunizing antigen dose; The OCR numeric threshold was not reproduced.

Slide 22 · ABO mismatch can reduce Rh sensitization

When fetal red cells carry ABO antigens

Natural maternal anti-A or anti-B can react with incompatible cells in maternal blood.

Those fetal cells are cleared more rapidly from maternal circulation.

Consequence for RhD

Less persistence of RhD-positive fetal cells may reduce Rh priming.

This protection does not imply that ABO incompatibility itself is always harmless.

Slide 23 · The ABO protection paradox

ABO-incompatible fetal RBC enters maternal blood

Maternal anti-A / anti-B reacts

Rapid RBC removal

Reduced RhD antigen exposure

The ABO reaction occurs on fetal cells circulating in maternal blood, not by maternal IgM crossing the placenta.

Slide 24 · Antigen mismatch is not equivalent to disease

Condition

What is established

What remains uncertain

RhD incompatibility

Maternal and fetal RhD differ

Whether the mother is sensitized

RhD alloimmunization

Maternal anti-D exists

Severity of fetal hemolysis

Immune hydrops

Severe antibody-mediated fetal disease

Degree of recovery after intervention

Condition

What is established

What remains uncertain

Slide 25 · Anti-D immune globulin prevents Rh sensitization

RhD-negative mother

Potential RhD-positive fetal-cell exposure

Rh immune globulin prophylaxis

Reduced subsequent alloimmunization

Passive anti-D prophylaxis reduces maternal sensitization risk.

Slide 26 · Textbook RhIg schedule targets two exposure windows

During gestation

Administration at approximately 28 weeks.

After RhD-positive delivery

Administration within 72 hours.

After pregnancy loss

Additional prophylaxis following abortions.

The schedule shown is the described Robbins regimen; Local clinical protocols may differ.

Slide 27 · Postpartum prophylaxis protects future pregnancies

Delivery-associated fetal RBC exposure

RhIg administered to the mother

Reduced active anti-D sensitization

Lower risk in a later pregnancy

Prophylaxis does not treat established severe fetal anemia.

Slide 28 · Other pregnancy events may also sensitize

Pregnancy loss or abortion can expose maternal blood to fetal erythrocytes.

Robbins specifically describes RhIg administration after abortions.

A previous exposure history changes the interpretation of risk in a later pregnancy.

Prevention targets maternal sensitization before clinically consequential fetal hemolysis.

Slide 29 · Fetal Rh status can be assessed antenatally

Maternal blood sample

Cell-free fetal DNA present

Analysis of RHD-related sequences

Assessment of fetal RhD status

Efforts to identify fetal Rh status using fetal DNA in maternal serum.

Slide 30 · Invasive testing historically aided risk assessment

Source-mentioned procedure

Diagnostic role in the historical framework

Amniocentesis

Antenatal assessment of an at-risk pregnancy

Chorionic villus sampling

Fetal / placental diagnostic evaluation

Fetal blood sampling

Direct evaluation of fetal blood in selected cases

Source-mentioned procedure

Diagnostic role in the historical framework

Slide 31 · Fetal anemia is the critical treatment target

Disease mechanism

Maternal IgG continues to drive fetal erythrocyte destruction.

Severe anemia produces cardiocirculatory stress.

Source-described intervention

Fetal intravascular transfusion via the umbilical cord.

Early delivery when clinically appropriate.

Slide 32 · Prevention and fetal treatment act at different stages

Strategy

Target

Temporal role

RhIg prophylaxis

Maternal immunization

Before immune disease becomes established

Fetal intravascular transfusion

Severe fetal anemia

During affected pregnancy

Early delivery

Continued intrauterine disease risk

Selected severe fetal cases

Strategy

Target

Temporal role

Slide 33 · ABO hemolytic disease uses a different entry point

Blood group O

Typical mother

Blood group A or B

At-risk infant

IgG antibody

ABO-mediated neonatal hemolysis occurs predominantly in A or B infants of O mothers.

Slide 34 · ABO disease may affect the firstborn

Before pregnancy

Some group O mothers already have IgG anti-A / anti-B.

First incompatible fetus

Maternal IgG reaches fetal circulation.

Neonatal hemolysis

Antibody-mediated erythrocyte clearance can occur.

Slide 35 · Most natural ABO antibodies are IgM

Maternal blood

Fetal blood

P

L

A

C

E

N

T

A

IgG

Reaches fetus

IgM

Does not cross

Most anti-A / anti-B antibodies are IgM, limiting placental transfer; A subset of group O mothers also possess IgG.

Slide 36 · Neonatal ABO antigen density is low

Fetal / neonatal red cells

A and B determinants are expressed at relatively low levels.

Less target antigen limits the intensity of antibody-mediated hemolysis.

Clinical implication

ABO incompatibility is much more frequent than clinically severe hemolysis.

Severe immune hydrops from ABO mismatch is unusual.

Slide 37 · Nonerythroid ABO antigens absorb some antibodies

Maternal IgG anti-A / anti-B

Placental transfer

Binding to several fetal cell types

Less antibody available for RBC injury

ABO antigens are expressed on tissues beyond erythrocytes.

Slide 38 · Three mechanisms limit ABO disease severity

Class of antibody

Most anti-A / anti-B is IgM and cannot cross placenta.

Antigen density

Neonatal erythrocytes have relatively little A / B antigen.

Antigen distribution

Nonerythroid cells can bind some transferred antibody.

Slide 39 · ABO mismatch is common; Severe disease is not

Textbook estimate

Interpretation

20–25% of pregnancies

ABO incompatibility

Approximately 1 in 10 incompatible infants

Hemolysis occurs

Approximately 1 in 200 incompatible cases

Hemolysis severe enough to require treatment

Textbook estimate

Interpretation

Slide 40 · RhD and ABO disease: Compare the mechanisms

Feature

RhD disease

ABO disease

Typical maternal setting

RhD-negative, sensitized

Group O with anti-A / anti-B IgG

Firstborn involvement

Uncommon classically

Possible

Dominant antibodies

IgG after sensitization

Mostly IgM; relevant IgG subset

Severe hydrops

Recognized complication

Rare

Feature

RhD disease

ABO disease

Slide 41 · A clinical distinction: Incompatible ≠ hemolyzed

Blood group incompatibility only identifies a possible antigen–antibody mismatch.

Antibody class, sensitization, and fetal antigen expression modify disease risk.

The downstream clinical phenotype ranges from little hemolysis to severe fetal disease.

Assess the mechanism and consequences; Do not infer hydrops from blood group alone.

Slide 42 · Hemolysis drives two major injury pathways

Excessive red-cell destruction

Reduced RBC mass

Fetal anemia → organ hypoxia → hydrops

Heme degradation

Unconjugated bilirubin → CNS toxicity

The two pathways vary independently in severity and timing.

Slide 43 · Compensatory erythropoiesis begins with anemia

RBC destruction exceeds survival

Fetal anemia

Increased erythroid production

Expansion of precursors

Mild hemolysis may be compensated; Severe hemolysis may outstrip production.

Slide 44 · Erythroid compensation may preserve RBC mass

When compensation succeeds

Higher red-cell production offsets some losses.

Anemia may remain modest despite ongoing hemolysis.

When compensation fails

RBC destruction exceeds marrow and extramedullary output.

Progressive anemia increases tissue hypoxia.

Slide 45 · Extramedullary hematopoiesis has a tissue footprint

Liver

Erythroid precursor production outside marrow.

Spleen

Additional extramedullary erythropoiesis.

Other sites

Lymph nodes and occasionally kidney, lung, or heart.

Slide 46 · Erythroblastosis fetalis describes immature RBCs

Compensatory erythroid hyperplasia

Premature release of erythroid cells

Circulating erythroblasts / reticulocytes

Erythroblastosis fetalis

This blood finding is a response to fetal anemia; It is not exclusively immune-mediated.

Slide 47 · Hepatosplenomegaly is mechanistically informative

Hematopoietic response

Expanded extramedullary erythropoiesis enlarges fetal liver and spleen.

Immature red-cell precursors may appear in circulating blood.

Hemodynamic response

Cardiac failure and congestion can also increase organ size.

Both processes can coexist in severe anemia-associated hydrops.

Slide 48 · Persistent anemia threatens oxygen delivery

Marked loss of red-cell mass

Inadequate tissue oxygenation

Cardiac and hepatic hypoxic injury

Progressive dysfunction

The degree of hemolysis determines how far this sequence progresses.

Slide 49 · Liver injury lowers plasma oncotic pressure

Severe anemia

Hepatic hypoxic injury

Reduced protein synthesis

Reduced plasma oncotic pressure

The source contains an implausible unit for a protein concentration; Numerical value intentionally omitted.

Slide 50 · Cardiac dysfunction raises hydrostatic pressure

Severe anemia / cardiac hypoxia

Cardiac decompensation

Circulatory congestion

Increased hydrostatic pressure

Raised vascular pressure favors outward movement of fluid.

Slide 51 · Hydrops combines two fluid-shifting forces

Hepatic injury

↓ plasma proteins

↓ oncotic pressure

Cardiac decompensation

↑ venous pressure

↑ hydrostatic pressure

Generalized fetal edema / anasarca

Slide 52 · Generalized edema is the final common phenotype

Anemia

Reduced oxygen delivery and compensatory erythropoiesis.

Organ dysfunction

Cardiac and hepatic injury affect vascular fluid balance.

Fetal phenotype

Diffuse subcutaneous and serous cavity fluid accumulation.

Slide 53 · Anemia-associated hydrops alters fetal morphology

Fetus

Pallor due to anemia.

Hepatosplenomegaly with congestion and hematopoiesis.

Placenta

Placental pallor is described in severe fetal anemia-associated hydrops.

Morphologic appearance alone does not establish an immune cause.

Slide 54 · A marrow response supports anemia-associated hydrops

Expected response

Compensatory erythroid precursor hyperplasia.

Extramedullary hematopoiesis can accompany severe anemia.

Important exception

Parvovirus B19 may damage erythroid precursors.

Marrow red-cell aplasia is therefore a nonimmune differential clue.

Slide 55 · Disease spectrum depends on hemolytic burden

Milder hemolysis

Compensation; Pallor ± organomegaly.

Progressive fetal anemia

Hypoxic stress and worsening dysfunction.

Severe disease

Anasarca, intense jaundice after birth, neurologic risk.

Slide 56 · Hemoglobin catabolism produces bilirubin

Red-cell destruction

Hemoglobin breakdown

Unconjugated bilirubin formation

Neonatal jaundice

Bilirubin production increases when erythrocyte destruction accelerates.

Slide 57 · Unconjugated bilirubin can injure the immature CNS

Excess unconjugated bilirubin

Exposure of immature blood–brain barrier

Brain tissue uptake

Bilirubin-associated neural injury

Clinical neonatal timing and bilirubin handling differ from the intrauterine period.

Slide 58 · Kernicterus has a characteristic CNS distribution

Deep gray nuclei

Basal ganglia and thalamus may appear yellow.

Other susceptible sites

Cerebellum, cerebral gray matter, spinal cord described.

Consequences

Serious bilirubin-associated central nervous system damage.

Slide 59 · Prematurity increases bilirubin vulnerability

Term neonate

A higher typical bilirubin threshold for kernicterus.

The precise individual injury threshold is unpredictable.

Premature neonate

Neural toxicity may occur at lower bilirubin levels.

Gestational maturity therefore modifies risk.

Slide 60 · Clinical features mirror the two injury pathways

Dominant process

Clinical manifestation

Mechanistic explanation

Red-cell loss

Pallor / anemia

Decreased erythrocyte mass

Compensation / congestion

Hepatosplenomegaly

Hematopoiesis and circulatory changes

Severe fetal organ stress

Generalized edema

Low oncotic + high hydrostatic forces

Bilirubin excess

Jaundice / neurologic injury

Unconjugated bilirubin toxicity

Dominant process

Clinical manifestation

Mechanistic explanation

Slide 61 · Phototherapy addresses neonatal bilirubin excess

Unconjugated bilirubin

Exposure to appropriate therapeutic light

Formation of more excretable products

Reduced bilirubin toxicity

This is neonatal management of hyperbilirubinemia, not prophylaxis of maternal Rh sensitization.

Slide 62 · Exchange transfusion treats severe neonatal disease

Treatment indication in principle

Severe hemolytic hyperbilirubinemia in a neonate.

Risk of serious bilirubin-related neurologic toxicity.

Source-mentioned action

Exchange transfusion in severe cases.

Specialist management rather than routine response to blood-group mismatch.

Slide 63 · Prevention and rescue target separate mechanisms

Clinical stage

Main pathology target

Source-described approach

Before maternal sensitization

Prevent maternal anti-D formation

Rh immune globulin

Severe intrauterine disease

Restore fetal red-cell mass

Umbilical intravascular transfusion

Severe neonatal bilirubin disease

Limit bilirubin toxicity

Phototherapy; exchange transfusion

Clinical stage

Main pathology target

Source-described approach

Slide 64 · Immune and nonimmune hydrops must be separated

Cause class

Examples from Robbins

Shared final phenotype

Immune

RhD and ABO antibodies

Fetal edema ± anemia

Nonimmune cardiac

Structural defects; fetal arrhythmias

Cardiac failure and edema

Nonimmune genetic

45,X; trisomy 21 or 18

Cardiac or lymphatic abnormalities

Nonimmune anemia

α-thalassemia; parvovirus B19

Severe fetal anemia and edema

Cause class

Examples

Shared final phenotype

Slide 65 · Case application: A sensitized RhD-negative mother

Illustrative teaching vignette

A previously sensitized RhD-negative mother carries a RhD-positive fetus. Severe fetal anemia develops.

Which maternal immunoglobulin produces fetal red-cell destruction?

Anti-D IgG can cross the placenta and bind fetal RhD-positive erythrocytes.

IgM is produced in a primary response but ordinarily does not cross the placenta.

Slide 66 · Case application: ABO disease in a firstborn

Illustrative teaching vignette

A group O mother delivers a firstborn infant with group A blood and neonatal jaundice.

Why is firstborn hemolysis possible in this setting?

Some group O mothers have preexisting IgG anti-A / anti-B antibodies.

ABO disease need not depend on pregnancy-induced Rh-type sensitization.

Slide 67 · Case application: From anemia to anasarca

Illustrative teaching vignette

A fetus with marked antibody-mediated anemia develops liver dysfunction, cardiac failure, and generalized edema.

Identify the two forces favoring edema.

Reduced plasma oncotic pressure and increased circulatory hydrostatic pressure.

Hepatic impairment lowers protein synthesis; Cardiac failure causes congestion.

Slide 68 · Read a hydrops presentation as a mechanism

Verify edema phenotype

Identify hemolytic anemia

Assess maternal–fetal antibody mechanism

Distinguish other fetal hydrops causes

This is a reasoning schematic from the textbook discussion—not a comprehensive clinical guideline.

Slide 69 · Five high-yield conclusions

Cause

Maternal IgG can mediate fetal erythrocyte destruction.

Difference

RhD often requires sensitization; ABO may affect a firstborn.

Consequence

Anemia drives fetal hydrops; Bilirubin excess threatens neonatal CNS.

Prevention

RhIg reduces maternal RhD sensitization.

Treatment

Severe fetal anemia and neonatal jaundice require distinct strategies.

Slide 70 · Reference and source boundaries

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. (2026). Chapter 10: Diseases of Infancy and Childhood, pp. 419–422.

Primary section: “Immune Hydrops”; surrounding sections: “Fetal Hydrops,” “Nonimmune Hydrops,” “Morphology,” and “Clinical Features.”

Conceptual diagrams are original editable schematics. No source photomicrographs or copyrighted textbook figures are reproduced.